Engage Therapeutics
Inhaled drug-device for rapid epileptic seizure termination
About Engage Therapeutics
Engage Therapeutics, Inc. was a clinical-stage biopharmaceutical company founded in 2017 by Greg Mayes and Jouko Isojarvi. The company focused on developing a rescue therapy for individuals experiencing uncontrolled epileptic seizures. Several of the company's founders and leaders had personal connections to epilepsy, driving their commitment to the field.
The company's main product was Staccato® alprazolam, a drug-device combination designed for the rapid termination of an active epileptic seizure, a condition known as Rapid Epileptic Seizure Termination (REST). This product consists of a small, hand-held inhaler that delivers the FDA-approved benzodiazepine, alprazolam. The Staccato® system works by rapidly vaporizing the drug into an aerosol with a particle size suitable for deep lung delivery, enabling a quick systemic effect. Clinical trial results showed it could stop seizure activity within two minutes of administration without recurrence within two hours. Engage Therapeutics acquired the worldwide rights to Staccato® alprazolam through an exclusive license and supply agreement with Alexza Pharmaceuticals in 2017.
The company's business model was centered on the clinical development and potential commercialization of this novel therapy, pursuing a 505(b)(2) regulatory pathway. It successfully raised $30.6 million in funding over two rounds from investors including TPG Biotech, Adage Capital Management, and Lumira Ventures. On June 5, 2020, Engage Therapeutics was acquired by UCB, a global biopharmaceutical company, for an initial payment of $125 million, with potential future milestone payments of up to $145 million. Following the acquisition, Engage Therapeutics became a wholly-owned subsidiary of UCB, which continues the development of Staccato® alprazolam.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- United States
- Open positions
- None listed
- Dealroom signal
- 19.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Epilepsy, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2017 | $24M | $94M | Granite Point Capital · Lumira Ventures · TPG · TPG Biotech | — |
Growth signals
Latest recorded traffic for Engage Therapeutics is 220 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Engage Therapeutics in its local ecosystem
The Engage Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
TPG- GCGranite Point Capital
Lumira Ventures
TPG Biotech
Adage Capital
Other known investors1 additional known investor
LifeSci Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Engage Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Engage Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







